8-tricycloalkyl xanthine derivatives
    1.
    发明授权
    8-tricycloalkyl xanthine derivatives 失效
    8-三环烷基黄嘌呤衍生物

    公开(公告)号:US5395836A

    公开(公告)日:1995-03-07

    申请号:US222938

    申请日:1994-04-05

    CPC分类号: C07D473/04 Y10S514/869

    摘要: There is provided a novel xanthine Compound(I) ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represent hydroxy-substituted, oxo-substituted or unsubstituted lower alkyl, Y is a single bond or alkylene, and Q is ##STR2## wherein R.sup.3 and R.sup.4 are the same or different and each represent hydrogen or hydroxy, n is 0 or 1; provided that when both of R.sup.3 and R.sup.4 are hydrogen, at least one of R.sup.1 and R.sup.2 is hydroxy-substituted or oxo-substituted lower alkyl; or a pharmaceutically acceptable salt thereof.The xanthine compound has adenosine A.sub.1 receptor antagonizing activity, and thus shows diuretic effect, renal-protecting effect, bronchodilatory effect, cerebral function improving effect and anti-dementia effect.

    摘要翻译: 提供了一种新颖的黄嘌呤化合物(I)其中R 1和R 2相同或不同,各自表示羟基取代的,取代或未取代的低级烷基,Y是单键或亚烷基,Q 其中R 3和R 4相同或不同,各自表示氢或羟基,n为0或1; 条件是当R 3和R 4都是氢时,R 1和R 2中的至少一个是羟基取代的或氧代取代的低级烷基; 或其药学上可接受的盐。 黄嘌呤化合物具有腺苷A1受体拮抗活性,因此具有利尿作用,肾保护作用,支气管扩张作用,脑功能改善作用和抗痴呆作用。